Navigation Links
Newly in Medical Technology

VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE

BEDFORD, Mass., July 30 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that scientists reporting in the July 31 issue of SCIENCE have discovered a key disease-related biologic pathway using an integrated and ...

Schering-Plough's Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study

A Phase II Study Published in The Lancet of Fast-Tracked Antiplatelet Agent Showed No Increase in TIMI Major and Minor Bleeding and was Well Tolerated When Given With Standard Platelet Therapy KENILWORTH, N.J., March 12 /PRNewswire-FirstCall/ -- Results of a Schering-Plough Corporation (NYSE:...

BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine

125 Patient, Prospective Randomized Placebo-Controlled Phase II Study Shows Statistically Significant Improved Overall Survival. MOUNTAIN VIEW, California, October 7 /PRNewswire/ -- BN ImmunoTherapeutics has now evaluated the mature Phase II data from the therapeutic prostate cancer vac...

Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine

KVISTGÃ…RD, Denmark, October 7 /PRNewswire-FirstCall/ -- - 125 Patient, Prospective Randomized Placebo-Controlled Phase II Study Shows Statistically Significant Improved Overall Survival Bavarian Nordic has now evaluated the mature phase II data from the therapeutic prostate cancer vaccine...

Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma

CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of results from three clinical trials of VELCADE based therapies that showed consistently high complete remission(1) (CR) rates in patients with newly diagnosed multiple my...

VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma

-- IFM presents updated results from Phase III clinical trial -- CHICAGO, May 31 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced the presentation of updated results from a 482 patient, multi-center, randomized Phase III clinical trial, comparing VEL...

New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma

- Five Oral Presentations at ASCO Annual Meeting Will Further Demonstrate the Strength of VELCADE Combinations in Front-line Multiple Myeloma - CAMBRIDGE, Mass., May 16 /PRNewswire/ -- Millennium Pharmaceuticals, The Takeda Oncology Company, today announced that new data from VELCADE clinica...

New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma

- Three large, randomized Phase III trials of VELCADE in front-line multiple myeloma to be featured as oral presentations at the American Society of Hematology (ASH) Annual Meeting - CAMBRIDGE, Mass., Nov. 26 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq:...

Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints

- Millennium on track to file sNDA in first quarter 2008 - CAMBRIDGE, Mass., Sept. 18 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced that the interim analysis results of the large, international Phase III VISTA(1) trial in patients with newly...

Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis

Levodopa Remains the Most Widely Prescribed Drug for Parkinson's Disease, According to a New Report from Decision Resources WALTHAM, Mass., Aug. 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issu...

Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma

-- U.S.-based trial to evaluate four-drug therapy containing highly active and novel multiple myeloma agents -- CAMBRIDGE, Mass., Aug. 15 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM ) today announced the initiation of a randomized, multi-center, Co...

Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia

HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Mar 19, 2007 - Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced positive results from its newly completed long-term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). 26 clinical trial sites across the U.S. and 116 unselected su...

MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer

PHILADELPHIA, March 28, 2007 /PRNewswire-USNewswire/ -- Magnetic Resonance Imaging (MRI) scans of women who were diagnosed with cancer in one breast detected over 90 percent of cancers in the other breast that were missed by mammography and clinical breast exam at initial diagnosis, according to a...

ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma

SUMMIT, N.J., April 04, 2007 /PRNewswire-FirstCall/ -- Celgene Corporation announced that the Eastern Cooperative Oncology Group (ECOG) has reported that its Data Monitoring Committee's (DMC) review of preliminary results from a large, randomized clinical trial for patients with newly diagnosed mu...

New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy

COLLEGEVILLE, Pa., April 03, 2007 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , provides comment on a re- analysis of pooled data from both hormone therapy arms of the Women's Health Initiative (WHI) Study published today in the Journal of the American Medical Association....

Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients

-- 100 percent response rate achieved with VELCADE, lenalidomide and dexamethasone KOS, Greece, June 28 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today reported on the presentation of results from four clinical trials of VELCADE based therapies that showed consist...

Scientists Discover Origin of Malaria

...my of Sciences, by identifying several new parasites from chimpanzees. The newly discovered parasites show that malaria jumped from animals to humans, much ...in human and chimpanzee ancestors for the last 5 million years. The newly discovered parasites not only demonstrate how malaria originated, but repre...

TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men

...ve Medicine's Menopausal Medicine , KLRI publications findings were twofold that there are certain benefits to menopausal hormone therapy (HT) in newly postmenopausal women, but that there are risks and a potential loss of benefit to estrogen therapy in women who have been postmenopausal for several y...

Study Shows Cancer Vaccines Led to Long-Term Survival for Patients with Metastatic Melanoma and to Long Periods of Disease Control After Completion of Therapy

...entered education and support programs. As the highest volume provider of cancer care in Orange County, Hoag Cancer Center manages approximately 2,000 newly diagnosed cancer patients each year, providing the latest state-of-the-art technology and treatment options. The center participates in a variety of c...

Cystic Fibrosis - Liposomal Tobramycin Receives Second Orphan Drug Designation Within Weeks

...go, the FDA granted Fluidosomes(TM)-tobramycin orphan drug designation for the treatment of pulmonary infections caused by Pseudomonas aeruginosa. The newly granted second designation relates to pulmonary infections caused by Burkholderia cepacia (B. cepacia) pathogens. Despite stringent infection c...

Bioniche Life Sciences Inc. and Endo Pharmaceuticals Sign Licensing Agreement for Urocidin(TM)

... America, bladder cancer is the fourth most common cancer in men and in the top ten for women. In the United States, approximately 70,000 patients are newly diagnosed with bladder cancer each year. In addition, the cancers of many previously-diagnosed patients remain unresolved, sometimes leading to cystec...

CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series

...from the different Multikine Phase II clinical trials which highlight the advantages that Multikine treatment provides for early disease management in newly diagnosed (treatment naive) patients with Squamous Cell Carcinoma of the Head and Neck. Early intervention in this disease is seen by many clinicians...

Landmark Study for GSK's Cervical Cancer Vaccine Published in The Lancet

... to mild, moderate or severe cell changes respectively. CIN 2+ is the surrogate marker for cervical cancer. Worldwide, more than 500,000 women will be newly diagnosed with cervical cancer and 280,000 women will die from it each year. HPV types 16, 18 and 45 are particularly important because these typ...

Cordex Signs European Development Partnership for ATPotent(TM) Sperm Motility Drug

...the results of the clinical trial for ATPotent(TM) may not be as expected, that our preclinical program to develop new chemical entities that target a newly discovered pathway in the pathophysiology of chronic obstructive pulmonary disease may not be successful, the market may not be as anticipated and tha...

Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions

...Plasma Glucose and Lipids in Diabetic Rodents (Oral Presentation) Authors: S.F. Murray, S.L. Booten, L.M. Watts, B.P. Monia, S. Bhanot. A newly Identified Role of Nuclear Receptor Corepressor, SMRT (Silencing Mediator of Retinoid and Thyroid) in Improving Hyperglycemia and Insulin Sens...

Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association

...t the DEFEND Study DEFEND is a randomized, placebo-controlled Phase 3 trial intended to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at multiple centers throughout Europe and North America. The trial is designed to eva...

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

...loma According to the American Cancer Society, in 2009, approximately 20,500 new cases of multiple myeloma will be diagnosed in the United States. newly diagnosed patients have treatment options that include combination chemotherapeutic agents and stem cell transplantation. While many patients respond...

New Study: Antidepressants Commonly Prescribed with Tamoxifen Put Women at Much Higher Risk for Recurrent Breast Cancer

...School of Medicine and a member of the research team. Study Details The study was a retrospective analysis of almost 1,300 women who were newly prescribed tamoxifen to treat breast cancer between 2003 and 2005 and were monitored for at least two years, with the average being 2.7 years. All st...

Perceptive Informatics Enhances Investigator Application of New RECIST Version in Imaging-Based Oncology Trials

...ifecycle. In August, 2008 Perceptive was joined with ClinPhone plc, and the newly combined organization offers eClinical software and services that increase ... the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not...

Mayo Researchers Help Discover Genetic Cause for Primary Biliary Cirrhosis

...e pathway and thus more amenable to treatment." The reliability of the newly discovered association is very strong; statistically, there's about a one i...re about the predisposing genetic factors to primary biliary cirrhosis. The newly discovered IL12 pathway does not account for all instances of primary bilia...

PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide

...in new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy ac...

Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research

...184 Call #1 from 12 PM to 1 PM EDT / (9 AM to 10 AM PDT) Conference Code: 10324648 Participants: 10 Researchers from the newly announced Dream Teams Nobel Laureate Phillip A. Sharp, Ph.D., Institute Professor at the Massachusetts Institute of Technology and David ...

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

...estigational eFlow Nebulizer System opens new treatment avenues and perspectives for patients and physicians. This expectation is further supported by newly published data on a potential antiviral efficacy of DSCG that may be particularly important in the treatment of pediatric asthma," added Dr. Manfred K...

Agennix Receives Fast Track Designation From FDA for Talactoferrin in Combination With Sunitinib for Renal Cell Carcinoma

...talactoferrin, and results are expected in 2011. FORTIS-C is a randomized, placebo-controlled trial evaluating 1100 chemo-naive NSCLC patients. newly diagnosed patients with Stage IIIB/IV NSCLC will be randomly assigned (1:1) to receive standard first-line chemotherapy with carboplatin and paclitaxe...

Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)

...ve Officer of UCB. "In addition, we are pleased to offer people with Crohn's disease in the U.S. the option of self-administering Cimzia(R) using this newly designed syringe. Cimzia(R) patients will now have the convenience of at-home self-injections," said Doliveux. "OXO(R) was built on the foundati...

Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery

... is approved for the treatment of patients with KIT (CD117)-positive GIST. In the EU, Glivec is also approved for the treatment of adult patients with newly diagnosed Ph+ acute lymphoblastic leukaemia (Ph+ ALL) in combination with chemotherapy and as a single agent for patients with relapsed or refractory ...

Perceptive Informatics Survey Results Reveal Top Barriers to Implementing Adaptive Trial Designs

...ifecycle. In August, 2008 Perceptive was joined with ClinPhone plc, and the newly combined organization offers eClinical software and services that increase ... the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not...

Arrayit to Mass Produce Rapid H1N1 Swine Flu Test Chip

...l advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the o...

Perceptive Informatics Introduces Medical Imaging Methodology to Accelerate Development Decisions About Alzheimer's Treatments

...ifecycle. In August, 2008 Perceptive was joined with ClinPhone plc, and the newly combined organization offers eClinical software and services that increase ... the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not...

Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests

...est for prostate cancer in the United States, Europe and around the world. As part of the amendment, Gen-Probe will acquire 4.9 million shares of newly issued DiagnoCure convertible preferred stock for US$5.0 million (C$6.1 million), representing a premium of 19.8% over the average market price of the...
Other Tags
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... software and services, previously announced on June 26, 2014 ... cash dividend of $1.75 per share, or approximately $40 ... of July 10, 2014 and a payment date of ... NASDAQ that it had set an ex-dividend date for ...
(Date:7/10/2014)... SHELTON, Conn. , July 2, 2014 NXT-ID, Inc., ... market, reports that CEO Mr. Gino Pereira was ... radio show in Tampa Florida . Mr. ... radio host Cedric Harris and how the Wocket™ ... secure alternative.  Cedric Harris tells ...
(Date:7/10/2014)... 2014 According to a new ... Control Systems Market Global Forecast, Market Share, Size, Growth ... Access Control systems market was valued at USD 15,406.1 ... a CAGR of 12.6% from 2014 to 2019, to ... 2019. Browse the full Electronic Access Control ...
Breaking Biology News(10 mins):NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 2Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 3Security and Your Money: Tampa Bay Radio Host Cedric Harris Talks to NXT-ID CEO Mr. Gino Pereira about the Wocket Smart Wallet 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 2Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 3Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 4Electronic Access Control Systems Market is Expected to Reach USD 31.2 Billion Globally in 2019: Transparency Market Research 5
(Date:7/13/2014)... 13, 2014 Max International ... Mullin, will be the featured guest at its Charity ... Puerto Rico. Attendees will learn about Max’s health ... two exhibition basketball games and perform in a 3 ... of health- and energy-boosting supplements , has recently announced ...
(Date:7/13/2014)... Dallas, Texas (PRWEB) July 13, 2014 ... of aGVHD in the 6MM, from 8,062 diagnosed incident ... 2023, at an Annual Growth Rate (AGR) of 4.35%, ... have the highest number of diagnosed incident cases of ... whereas Spain will have the lowest number of diagnosed ...
(Date:7/13/2014)... According to the Kidney Disease Solution book review ... guide on what to do to eliminate the root ... in its review that readers can easily learn what foods ... kidney health. Vkool also informs in its Kidney Disease Solution ... kidney functions naturally. The book consists of a collection of ...
(Date:7/13/2014)... Celebrity fitness trainer and former World ... partnership with Aqua Health Labs for their flagship product ... . The collaboration was recently announced live on ESPN ... , actor, model, and a two time World Super ... he has prepared stars including Demi Moore, Hilary Swank ...
(Date:7/13/2014)... If Dr. Lawrence Power has his way, the ... http://www.HealthYourself101.com will expand people’s understanding of the causes, ... set out to provide a health education platform on this ... we say it? – entertaining to dig into and learn ... the remote learner – the solitary individual signing on from ...
Breaking Medicine News(10 mins):Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 2Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 3Health News:Max International Announces NBA Dream Team Member Chris Mullin as Featured Guest of Charity Event 4Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 2Health News:Kidney Disease Solution Book Review Exposes Duncan Capicchiano's Newly Updated Kidney Disease Treatment Plan – Vkool.com 3Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4
Other Contents